PRTA: Prothena Corporation P/S multiplikatori
Prothena Corporation (PRTA) amiloid patologiyalarini davolash bo'yicha asosiy hamkorlardan tushadigan royalti va to'lovlar orqali daromad keltiradi. P/S koeffitsiyenti tendentsiyasi bozor optimizmini tasdiqlaydi, bunda 8.00 ushbu baholash parametrini xarakterlaydi. Neyromeditsinadagi yuqori nufuz aksiyadorlarning ishonchini mustahkamlaydi, garchi geosiyosiy taranglik va logistik murakkabliklar xorijiy klinik sinovlarni o'tkazish hamda komponentlarni yetkazib berishga to'sqinlik qilishi mumkin bo'lsa-da.
Prothena Corp (PRTA) kompaniyasi koʻrsatkichlari kesimi va tahlili
- aksiya narxi va konsensus maqsadli narx:
- bozor kapitallashuvi haqida ma'lumot:
- balans bo'yicha xususiy kapital ma'lumotlari:
- biznesning qarz tarkibi va likvidligi tafsilotlari:
Qarzning kapitalga nisbati Prothena Corporation|PRTA - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati Prothena Biosciences|PRTA - Kompaniya qarzlari|Qarzlarning balans kapitallashuviga nisbati Prothena Corp|PRTA - Kompaniyaning uzoq muddatli qarzi|Qisqa muddatli qarz Prothena|Oraliq qoplash koeffitsiyenti prothena.com
- foyda va qiymat multiplikatorlari haqida ma'lumot:
PRTA - Sof foyda|Prognoz qilingan kelajakdagi foyda Prothena Corporation|PRTA - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning kelajakdagi foydaga nisbati Prothena|PRTA - PEG multiplikatori|Kompaniyaning to‘liq qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati Prothena Corp|PRTA - Foizlar, soliqlar va eskirish to'lanishidan oldingi foyda|So'nggi o'n ikki oy davomida bitta aksiya uchun sof foyda Prothena|PRTA - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi 12 oy davomida bir aksiya uchun foydaning yillik o'sishi prothena.com|PRTA - Joriy yilda bir aksiya uchun foyda o'sishi|Kelgusi yil uchun bir aksiya uchun sof foydaning o'zgarishi prognozi Prothena Corporation
- emitentning tushumi va sotuvlari tafsilotlari:
Kompaniyaning fundamental tahlili:prothena.com - PRTA
P/S koeffitsiyenti biznesning bozor qiymatini uning yillik savdo hajmi bilan nisbatda belgilaydi va operatsion xarajatlarni hisobga olmagan holda aktivlarni monetizatsiya qilish samaradorligini baholash imkonini beradi. Neyrodegenerativ kasalliklar bo'yicha ishlanmalari klinik sinovlarning so'nggi bosqichida bo'lgan Prothena Corporation (PRTA) uchun kompaniyaning tekislangan P/S koeffitsiyenti mahsulotlar ommaviy savdo bosqichiga yetib borguncha, inqilobiy terapevtik antitelalarning kelgusidagi tijoratlashtirilishiga nisbatan bozor kutganlarini aks ettiradi.
Prothena Corporation raqobatchilari
biogen.com - Kapitalizatsiya va daromad nisbati|P/S multiplikatori NBIX (Neurocrine Biosciences, Inc.)|P/S multiplikatori Regencell Bioscience Ltd RGC|AXSM: Kapitalizatsiyaning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati ACAD (ACADIA Corp)|XENE: P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati vikingtherapeutics.com|Narxning daromadga nisbati Supernus|Sotuvga nisbatan narx Catalyst Pharma CPRX|Narxning daromadga nisbati Denali Therapeutics Inc (DNLI)|HRMY (Harmony Corp) - Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati Biohaven Ltd. BHVN|AMLX (amylyx.com) - Narxning sotuvga nisbati|TRVI - Narxning daromadga nisbati|Sotuvga nisbatan narx Praxis Precision Medicines Inc|Anavex Corp (AVXL) - Narxning daromadga nisbati|CeriBell EEG - Bozor kapitallashuvining daromadga nisbati|ALEC (Alector Inc.) - P/S multiplikatori|P/S multiplikatori annexonbio.com|Kapitalizatsiyaning daromadga nisbati OMER (Omeros Corporation)|Kapitalizatsiyaning sotish hajmiga nisbati NGNE|P/S multiplikatori ACIU (AC Immune Corp)|Narx/daromad koeffitsiyenti Voyager Corp (VYGR)|NMRA - Narxning daromadga nisbati|Sotuvga nisbatan narx scilexholding.com|Tevogen Bio (TVGN) - Narxning daromadga nisbati|Kapitalizatsiya va daromad nisbati ACOG|Narxning daromadga nisbati Cognition Therapeutics, Inc.|Inhibikase Pharma - Narxning sotuvga nisbati|Narxning daromadga nisbati Cassava Sciences, Inc. (SAVA)|ASRT (assertiotx.com) - Bozor kapitallashuvining daromadga nisbati|Coya Therapeutics - Kapitalizatsiyaning daromadga nisbati|Kapitalizatsiyaning sotish hajmiga nisbati VTGN (VistaGen Therapeutics, Inc.)|Ovid Rx - P/S multiplikatori|ABOS - P/S multiplikatori|CervoMed Inc. (CRVO) - Narxning daromadga nisbati|Kapitalizatsiya va daromad nisbati ATHE|CLNN (Clene Inc) - P/S multiplikatori|Sotuvga nisbatan narx PepGen Corp PEPG|Kapitalizatsiyaning daromadga nisbati JUNS (Jupiter Neurosciences)|P/S multiplikatori Relmada Corp (RLMD)|Narxning daromadga nisbati Annovis Bio, Inc. ANVS|Bozor kapitallashuvining daromadga nisbati GRCE|AIFF - Narxning daromadga nisbati|Sotuvga nisbatan narx Klotho Neurosciences Inc|neurosense-tx.com (NRSN) - Narxning daromadga nisbati|Narxning sotuvga nisbati RVPH (Reviva Pharmaceuticals, Inc.)|Narxning daromadga nisbati MetaVia Inc.|NRXS: Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati Helius Medical (HSDT)|PASG - Sotuvga nisbatan narx|Neuphoria Therapeutics - Kapitalizatsiyaning daromadga nisbati|Kapitalizatsiyaning sotish hajmiga nisbati NERV (Minerva)|Athira Pharma, Inc. - P/S multiplikatori|Bozor kapitallashuvining daromadga nisbati ADXN (addextherapeutics.com)|ALZN: P/S multiplikatori|Sotuvga nisbatan narx Cyclerion Therapeutics, Inc. (CYCN)|Narxning daromadga nisbati Protagenic Therapeutics Inc.|Kapitalizatsiya va daromad nisbati KTTA (Pasithea)|P/S multiplikatori CRGT|P/S multiplikatori avenuetx.com (ATXI)|BrainStorm Cell Therapeutics - Kapitalizatsiyaning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati CARA|Chromocell Therapeutics Corporation - P/S multiplikatori|Eliem Therapeutics (ELYM) - Kapitalizatsiyaning daromadga nisbati|intracellulartherapies.com (ITCI) - Narxning daromadga nisbati|Sotuvga nisbatan narx longboardpharma.com (LBPH)|Narxning daromadga nisbati Marinus Pharmaceuticals, Inc.|NKGN: Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati NeuroBo (NRBO)|SAGE: Narxning sotuvga nisbati|Narxning daromadga nisbati Synaptogenix, Inc. SNPX|trevena.com (TRVN) - Sotuvga nisbatan narx|VIGL - Narxning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati WENA (anewmeds.com)|CERE: P/S multiplikatori
